The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin.
Open Access
- 1 September 1992
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 176 (3), 751-760
- https://doi.org/10.1084/jem.176.3.751
Abstract
FK-506 inhibits Ca(2+)-dependent transcription of lymphokine genes in T cells, and thereby acts as a powerful immunosuppressant. However, its potential therapeutic applications may be seriously limited by several side effects, including nephrotoxicity and neurotoxicity. At present, it is unclear whether these immunosuppressive and toxic effects result from interference with related biochemical processes. FK-506 is known to interact with FK-binding protein-12 (FKBP-12), an abundant cytosolic protein with cis-trans peptidyl-prolyl isomerase activity (PPIase) activity. Because rapamycin (RAP) similarly binds to FKBP-12, although it acts in a manner different from FK-506, by inhibiting T cell responses to lymphokines, such an interaction with FKBP-12 is not sufficient to mediate immunosuppression. Recently, it was found that the complex of FKBP-12 with FK-506, but not with RAP, inhibits the phosphatase activity of calcineurin. Here, we used L-685,818, the C18-hydroxy, C21-ethyl derivative of FK-506, to explore further the role of FKBP-12 in the immunosuppressive and toxic actions of FK-506. Although L-685,818 bound with high affinity to FKBP-12 and inhibited its PPIase activity, it did not suppress T cell activation, and, when complexed with FKBP-12, did not affect calcineurin phosphatase activity. However, L-685,818 was a potent antagonist of the immunosuppressive activity of both FK-506 and RAP. Moreover, L-685,818 did not induce any toxicity in dogs and rats or in a mouse model of acute FK-506 nephrotoxicity, but it blocked the effect of FK-506 in this model. Therefore, FK-506 toxicity involves the disruption of biochemical mechanisms related to those implicated in T cell activation. Like immunosuppression, this toxicity is not due to the inhibition of the PPIase activity of FKBP-12, but may be linked to the inhibition of the phosphatase activity of calcineurin by the drug FKBP-12 complex.This publication has 34 references indexed in Scilit:
- FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurinNature, 1992
- Cyclosporin A, FK-506, and Rapamycin: Pharmacologic Probes of Lymphocyte Signal TransductionAnnual Review of Immunology, 1992
- A rapamycin-selective 25-kDa immunophilinBiochemistry, 1992
- Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexesCell, 1991
- TOXICITY OF RAPAMYCIN—A COMPARATIVE AND COMBINATION STUDY WITH CYCLOSPORINE AT IMMUNOTHERAPEUTIC DOSAGE IN THE RATTransplantation, 1991
- FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytesCellular Immunology, 1991
- Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A?The Journal of Experimental Medicine, 1991
- A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilinNature, 1989
- CalcineurinAdvances in enzymology and related subjects of biochemistry, 1988
- Cyclophilin: A Specific Cytosolic Binding Protein for Cyclosporin AScience, 1984